Survodutide: When It Will Be Available, Phase 3 Results and Side Effects

When will survodutide be available?

Not before FDA approves it, and no filing has been announced. Boehringer Ingelheim has reported two phase 3 weight trials, SYNCHRONIZE-1 in June 2026 and SYNCHRONIZE-2 in October 2026 ^{[2] [1]}. Neither announcement gave a date for regulatory submissions. The next result Zealand named is SYNCHRONIZE-CVOT, a heart outcomes trial, expected later in 2026 ^[1].

Once a company files a complete application, FDA says its review takes 6 to 10 months ^[4]. Until then there is no release date. Follow it in our GLP-1 pipeline tracker. You can also read where CagriSema, MariTide and amycretin stand.

Survodutide phase 3 results

Both trials gave survodutide 3.6 mg or 6.0 mg weekly, or placebo, for 76 weeks ^{[2] [1]}. The headline figures use the efficacy estimand, which assumes people stayed on treatment. Counting everyone who started, the figures are smaller.

Survodutide phase 3 weight results at 76 weeks

Trial	Who was in it	Survodutide	Placebo	Lost at least 5%	Source
SYNCHRONIZE-1	725 adults with obesity or overweight, without type 2 diabetes	Up to -16.6% (efficacy estimand)	-3.2%	Up to 85.1% vs 38.8%	[2] [3]
SYNCHRONIZE-2	755 adults with obesity or overweight and type 2 diabetes	Up to -13.1% (efficacy estimand); -8.2% and -9.8% counting everyone	-3.1%; -3.9% counting everyone	Up to 79.3% vs 32.7%	[1] [5]

In SYNCHRONIZE-2, A1C fell by up to 1.21 points from a starting average of 7.4%, vs 0.03 on placebo, and up to 29.5% reached an A1C under 5.7%, vs 4.0% ^[1]. In a body composition substudy of SYNCHRONIZE-1, visceral fat fell by up to 34.0% and liver fat by up to 63.1%, and lean mass made up no more than 10.8% of the tissue lost at the highest dose ^[2].

Survodutide side effects

The most common side effects were nausea, vomiting, diarrhea and constipation, mostly mild to moderate and mostly during dose increases ^[2]. Many people stopped: 19% stopped because of stomach side effects in SYNCHRONIZE-1, vs 2.9% on placebo ^[2], and 18% in SYNCHRONIZE-2, vs 1.2% ^[1]. Boehringer says it plans new dosing guidance, and a phase 3b study, SYNCHRONIZE-START, will focus on tolerability ^[2].

How survodutide works

Survodutide is a dual agonist: it activates the GLP-1 receptor, like Wegovy, and the glucagon receptor ^[3]. Boehringer is also testing survodutide in MASH, a fatty liver disease, and it holds an FDA Breakthrough Therapy designation for MASH with liver scarring ^[5]. For background, see how GLP-1 drugs work.

Survodutide vs Wegovy and Zepbound

No head-to-head trial has been reported. The table puts each drug's main obesity trial in adults without diabetes side by side. The trials differ, so this is not a ranking.

Survodutide, Wegovy and Zepbound: status and main obesity trial

	Survodutide	Wegovy (semaglutide)	Zepbound (tirzepatide)
FDA status	Not approved [1]	Approved	Approved
Receptors	Glucagon and GLP-1 [3]	GLP-1	GIP and GLP-1 [6]
Main trial	SYNCHRONIZE-1, 76 weeks [2]	STEP 1, 68 weeks [7]	SURMOUNT-1, 72 weeks [8]
Average weight change	Up to -16.6% vs -3.2%, efficacy estimand [2]	-14.9% on 2.4 mg vs -2.4% [7]	-20.9% on 15 mg vs -3.1% [8]
Self-pay price a month	None	$199 to $399, NovoCare, checked Oct 17, 2026 [9]	$299 to $449, LillyDirect, checked Oct 17, 2026 [10]

See Wegovy vs Zepbound, Zepbound cost and Wegovy cost.

How to get survodutide legally

Only in a clinical trial. Search open studies on ClinicalTrials.gov. FDA says it has warned companies selling survodutide and other GLP-1 products labeled "for research purposes" or "not for human consumption," and that those products have unknown quality and may be harmful ^[11]. See research-use-only GLP-1s and the approved options in online GLP-1 programs.

How we check

Results come from Zealand Pharma's company announcements, which report Boehringer's data, and from trade coverage of the published trial. We name the estimand for each number. When Boehringer files or FDA acts, this page and the pipeline tracker change.